Forward catalyst · GMAB

acasunlimab

Sponsor Genmab A/S · listed as GMAB

READOUT Phase 3 Confidence: medium Source: clinicaltrials

acasunlimab is a clinical-stage drug asset sponsored by Genmab A/S, listed as GMAB. CSA tracks 1 forward catalyst for it — the nearest is a readout expected Jul 30, 2027 (day precision, medium confidence), tied to trial NCT06635824. The asset is in Phase 3 and currently active not recruiting, studied in PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC.

Next catalyst

Event typeREADOUT

Expected date2027-07-30

As disclosedJul 30, 2027

Date precisionday

Confidencemedium

Verify at source →

Trial & sponsor

Trial (NCT)NCT06635824

PhasePHASE3

StatusACTIVE_NOT_RECRUITING

Lead sponsorGenmab

Listed asGMAB

Condition(s)PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC

Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.

This is one row of the free CSA sample. The full snapshot carries 2,103 forward catalysts across 139 listed sponsors.

Get the full dataset — $499 → More GMAB catalysts